Business Wire

NTT-DATA

8.2.2024 09:01:34 CET | Business Wire | Press release

Share
NTT DATA Report Signals a Paradigm Shift as Banks Finally Migrate from Mainframes to AI-driven Cloud Technologies

NTT DATA, a global digital business and IT services leader, today announced a new global banking research report entitled "The Digital Horizon: Banking’s Shift from Mainframe to AI-Driven Cloud Infrastructure.” The research has unveiled findings from a survey of 650 global banking decision-makers, marking a definitive shift in the sector towards agile and customer-focused banking. Moreover, the survey uncovers a transformative trend: banks are finally pivoting from entrenched mainframe systems to adopt AI and cloud technologies, spurred by the multiple headwinds they face of consumer demands, innovative new market disruption, and the competitive pressures of innovative technological advancements.

Modernisation and Transformation Trends:

  • Enduring Mainframes: Despite 89% of banking leaders identifying as innovators, 63% still operate on mainframe systems, confirming the mainframe’s resilience.
  • Cloud Migration to Increase from Generative AI injection: 63% of banking decision-makers confirm generative AI is decisively facilitating the transition of banking applications to the cloud
  • Generative AI Gaining Board-Level Support: A resounding 91% report their AI and cloud initiatives are endorsed by the board, signalling strategic prioritisation.
  • Navigating Skill Gaps: With 80% lacking a strategic framework for generative AI adoption, the need for upskilling is evident.
  • 45% of banks are already integrating generative AI technology into their technology stacks while a further 30% are in the early stages of looking at it.
  • Cloud as an Innovation Enabler: Flexibility and scalability are cited by 36% of respondents as key drivers for cloud migration, indicating a shift beyond cost concerns.

The enduring stronghold of mainframes in the banking sector is poised for a significant shift, thanks to the integration of generative AI into cloud migration strategies. NTT DATA's research reveals that 63% of banking decision-makers confirm generative AI is decisively facilitating the transition of banking applications to the cloud, indicating a transformative phase where mainframes’ resilience meets the agility of cloud computing.

25% of respondents also acknowledge a growing trend in cloud migration, propelled by AI advancements. This heralds a new era where the collaboration between AI’s potential to reinterpret legacy code and cloud technology's scalability is accelerating modernisation and transformation initiatives, suggesting that the longstanding reign of mainframes is approaching its horizon.

Kaz Nishihata, Director and Senior Executive Vice President at NTT DATA Group Corporation, commented: "Banks are not only evolving technologically but also culturally. The industry’s rapid adoption of AI and cloud is redefining business models and establishing a new norm in sector leadership. This technological tide is propelling banks toward a more intimate understanding of customer needs, delivering services that are faster, more secure, and uniquely tailored."

The research also found that the banking industry is rapidly embracing the transformative power of generative AI, with 45% of banks already incorporating it into their operations. Additionally, 30% are exploring its potential, signalling a proactive shift towards innovation. This adoption underscores the sector's commitment to future-proofing services and the desire for organisations to enhance their competitive edge in a fast-evolving digital landscape.

Nishihata adds, “The momentum for generative AI across the banking sector is a testament to the industry’s resolve to move beyond traditional mainframes, leveraging cloud environments to fortify security, enhance robustness, innovate, and boldly redefine. This transition promises a new era of innovation.”

To read the full report, visit "The Digital Horizon: Banking’s Shift from Mainframe to AI-Driven Cloud Infrastructure"

About the research

NTT DATA's survey canvasses a diverse array of banking professionals, from all global banking markets, and provides a 360-degree perspective on the sector's modernisation and journey towards innovation and transformation.

Demographics of Respondents:

  • Global Insights: Leaders from a broad geographic spectrum, including the United States, the United Kingdom, Japan, Germany, Spain, Italy, Mexico, and Brazil.
  • Institutional Scope: A cross-section from multinational banks to local banking institutions.
  • Expertise Range: Perspectives across IT, Operations, Innovation, and Strategy.

About NTT DATA

NTT DATA – a part of NTT Group – is a trusted global innovator of IT and business services headquartered in Tokyo. We help clients transform through consulting, industry solutions, business process services, IT modernisation and managed services. NTT DATA enables clients, as well as society, to move confidently into the digital future. We are committed to our clients’ long-term success and combine global reach with local client attention to serve them in over 50 countries. Visit us at nttdata.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240208750914/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye